1. Bignotti, E., Ravaggi, A., Tassi, RA., et al. Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer 2008, 99(5), p. 768–773.
2. Bonkhoff, H., Stein, U., Welter, C., et al. Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum Pathol, 1995, 26(8), p. 824–828.
3. Borthwick, JM., Charnock-Jones, DS., Tom, BD., et al. Determination of the transcript profile of human endometrium. Mol Hum Reprod, 2003, 9(1), p. 19–33.
4. Cappelletti, V., Coradini, D., Scanziani, E., et al. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. Eur J Cancer, 1992, 28A(8–9), p. 1315–1318.
5. Foekens, JA., Rio, MC., Seguin, P., et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res, 1990, 50(13), p. 3832–3827.
6. Fox, JG., Rogers, AB., Whary, MT., et al. Accelerated progression of gastritis to dysplasia in the pyloric antrum of TFF2 -/- C57BL6 x Sv129 Helicobacter pylori-infected mice. Am J Pathol, 2007, 171(5), p. 1520–1528.
7. Hanby, AM., Poulsom, R., Elia, G., et al. The expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in ‚gastric metaplasia‘ of the proximal duodenum: implications for the nature of ‚gastric metaplasia‘. J Pathol, 1993, 169(3), p. 355–360.
8. Hanby, AM., Poulsom, R., Singh, S., et al. Spasmolytic polypeptide is a major antral peptide: distribution of the trefoil peptides human spasmolytic polypeptide and pS2 in the stomach. Gastroenterology, 1993, 105(4), p. 1110–1116.
9. Hauser, F., Poulsom, R., Chinery, R., et al. hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus. Proc Natl Acad Sci U S A, 1993, 90(15), p. 6961–6965.
10. Henry, JA., Bennett, MK., Piggott, NH., et al. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer, 1991, 64(4), p. 677–682.
11. Higashiyama, M., Doi, O., Kodama, K., et al. Estimation of serum level of pS2 protein in patients with lung adenocarcinoma. Anticancer Res, 1996, 16(4B), p. 2351–2355.
12. Ishibashi, Y., Ohtsu, H., Ikemura, M., et al. Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer. Sci Rep, 2017, 7(1), p. 4846.
13. Jorgensen, KH., Thim, L., Jacobsen, HE. Pancreatic spasmolytic polypeptide (PSP): I. Preparation and initial chemical characterization of a new polypeptide from porcine pancreas. Regul Pept, 1982, 3(3–4), p. 207–219.
14. Kao, LC., Tulac, S., Lobo, S., et al. Global gene profiling in human endometrium during the window of implantation. Endocrinology, 2002, 143(6), p. 2119–2138.
15. Masiakowski, P., Breathnach, R., Bloch, J., et al. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 1982, 10(24), p. 7895–7903.
16. Maxwell, GL., Chandramouli, GV., Dainty, L., et al. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res, 2005, 11(11), p. 4056–4066.
17. May, FE., Westley, BR. Expression of human intestinal trefoil factor in malignant cells and its regulation by oestrogen in breast cancer cells. J Pathol, 1997, 182(4), p. 404–413.
18. Mhawech, P., Benz, A., Cerato, C., et al. Downregulation of 14–3–3 sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol, 2005, 18(3), p. 340–348.
19. Mickova, I., Pilka, R., L‘ubusky, M., et al. [Molecular prognostic factors and pathogenesis of endometrial cancer]. Ces Gynekol, 2006, 71(4), p. 355–360.
20. Mika, O., Koznarova, J., Sak, P. [Ultrasound staging of stage I–II endometrial cancer, analysis of own file in the years 2012–2016]. Ces Gynekol, 2017, 82(3), p. 218–226.
21. Neubert, D., Pilka, R., Stejskal, D., et al. [The role of trefoil factor family in gynecological disease]. Ces Gynekol, 81(6), p. 444–450.
22. Pallud, C., Le Doussal, V., Pichon, MF., et al. Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumours. Histopathology, 1993, 23(3), p. 249–256.
23. Piggott, NH., Henry, JA., May, FE., et al. Antipeptide antibodies against the pNR-2 oestrogen-regulated protein of human breast cancer cells and detection of pNR-2 expression in normal tissues by immunohistochemistry. J Pathol, 1991, 163(2), p. 95–104.
24. Playford, RJ., Marchbank, T., Chinery, R., et al. Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology, 1995, 108(1), p. 108–116.
25. Podolsky, DK., Lynch-Devaney, K., Stow, JL., et al. Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem, 1993, 268(9), p. 6694–6702.
26. Poulsen, SS., Thulesen, J., Christensen, L., et al. Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat. Gut, 1999, 45(4), p. 516–522.
27. Poulsom, R., Hanby, AM., Lalani, EN., et al. Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol, 1997, 183(1), p. 30–38.
28. Probst, JC., Zetzsche, T., Weber, M., et al. Human intestinal trefoil factor is expressed in human hypothalamus and pituitary: evidence for a novel neuropeptide. FASEB J, 1996, 10(13), p. 1518–1523.
29. Rio, MC., Bellocq, JP., Daniel, JY., et al. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science, 1988, 241(4866), p. 705–708.
30. Risinger, JI., Maxwell, GL., Chandramouli, GV., et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003, 63(1), p. 6–11.
31. Semple, JI., Newton, JL., Westley, BR., et al. Dramatic diurnal variation in the concentration of the human trefoil peptide TFF2 in gastric juice. Gut, 2001, 48(5), p. 648–655.
32. Slama, J., Kocian, R. [Technique of pelvic and paraaortic lymphadenectomy]. Ces Gynekol, 81(4), p. 253–264.
33. Suemori, S., Lynch-Devaney, K., Podolsky, DK. Identification and characterization of rat intestinal trefoil factor: tissue- and cell-specific member of the trefoil protein family. Proc Natl Acad Sci U S A, 1991, 88(24), p. 11017–11021.
34. Thim, L. A new family of growth factor-like peptides. ‚Trefoil‘ disulphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP), and frog skin peptides (spasmolysins). FEBS Lett, 1989, 250(1), p. 85–90.
35. Tomasetto, C., Rio, MC., Gautier, C., et al. hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma. EMBO J, 1990, 9(2), p. 407–414.
36. Vestergaard, EM., Poulsen, SS., Gronbaek, H., et al. Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem, 2002, 48(10), p. 1689–1695.
37. Weinberger, V., Minar, L., Felsinger, M., et al. [Postoperative administration of octreotide to reduce lymphorrhea, lymphocele, lymphedema and lymphatic ascites after lymphadenectomy in gynecological malignancies]. Ces Gynekol, 2017, 82(2), p. 92–99.
38. Yamaguchi, J., Mino-Kenudson, M., Liss, AS., et al. loss of trefoil factor 2 from pancreatic duct glands promotes formation of intraductal papillary mucinous neoplasms in mice. Gastroenterology 2016, 151(6), p. 1232–1244 e10.